CSF2 and prostate carcinoma: We used the published data of an open-label, Phase II clinical trial of neoadjuvant sipuleucel-T [16, 17] and a Phase I/II clinical trial of ipilimumab with a fixed dose of GM-CSF to metastatic castration resistant prostate cancer patients [10] as the two test cases.